Nathan Martin

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Yi Lin, Noopur Raje, Jesús G. Berdeja et al. · Nature Medicine · 2023 · 118 citations · Full text

Medicine, Immunology, Oncology +17

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Melissa Alsina, Nina Shah, Noopur Raje et al. · Blood · 2020 · 85 citations

Medicine, Hematology, Immunology +17

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur Raje, Nina Shah, Sundar Jagannath et al. · Blood · 2021 · 80 citations

Medicine, Hematology, Oncology +16

ATM–Dependent MiR-335 Targets CtIP and Modulates the DNA Damage Response

Nathan Martin, Kotoka Nakamura, Robert C. Davies et al. · PLoS Genetics · 2013 · 53 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs

Peiyee Lee, Nathan Martin, Kotoka Nakamura et al. · Nature Communications · 2013 · 40 citations · Full text

Medicine, Molecular Genetics, Pharmacology +6